The Patent Finder
AB

Avidity Biosciences, Inc.

First filing 2017
OverviewNotableFeesChangesFamiliesPatent listSources & methods

36 patents currently held

19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Mar 2037. from the record

Of the 19 now held by other companies, 19 name Atrium Therapeutics Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2037
Next term end
11
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy US 11,246,941
Cited by 68 later US patents, top 1% of utility patents granted in 2022 in our data. Protection runs to 2038.
Ends Dec 2038 · Medium confidence
Also notable
Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping US 10,994,020
The most cited patent in this portfolio, cited by 107 later US patents, top 1% of utility patents granted in 2021 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2038 · Low confidence
Also notable
Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy US 11,525,137
Cited by 13 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2041 · High confidence

Formerly held, still cited

Notable
Cited by 70 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039.
Ends Dec 2039 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jan 25, 2027
    The maintenance fee for Compositions and Methods of Treating Muscle Dystrophy (US 11,707,532) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
  • 1 fee due Feb 1, 2027
    The maintenance fee for Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy (US 11,712,478) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
  • 1 fee due Jul 16, 2027
    The maintenance fee for Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy (US 11,872,287) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
  • 1 fee due Aug 27, 2027
    The maintenance fee for Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy (US 11,912,779) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 10,844,385Beta-Catenin Nucleic Acids and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,858,656Kras Nucleic Acids and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,876,121Egfr Nucleic Acids and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,994,020Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
In force
 · Low confidence
In forceLow confidence
US 11,179,472Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
In force
 · Low confidence
In forceLow confidence
US 11,311,627Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
In force
 · Low confidence
In forceLow confidence
US 11,400,163Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
In force
 · Low confidence
In forceLow confidence
US 12,064,483Nucleic Acid-Polypeptide Compositions and Methods of Inducing Exon Skipping
In force
 · Low confidence
In forceLow confidence
US 10,881,743Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy
In force
 · Medium confidence
In forceMedium confidence
US 11,246,941Compositions and Methods of Treating Muscle Atrophy and Myotonic Dystrophy
In force
 · Medium confidence
In forceMedium confidence
10 of 36 patents shown.
Pro members see all 36.
Pro members: see all 36 patents
Also on record, not counted in the 36: 19 patents in force now held by others · 31 applications pending · 12 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited